Get the Stockscreener App
1.63
0.00%
0.01
Outlook Therapeutics Inc stock is traded at $1.63, with a volume of 308.81K.
It is up +0.00% in the last 24 hours and down -28.54% over the past month.
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
See More
Previous Close:
$1.64
Open:
$1.66
24h Volume:
308.81K
Relative Volume:
0.15
Market Cap:
$52.51M
Revenue:
-
Net Income/Loss:
$-51.50M
P/E Ratio:
-0.4075
EPS:
-4
Net Cash Flow:
$-47.10M
1W Performance:
-12.30%
1M Performance:
-28.54%
6M Performance:
-77.44%
1Y Performance:
-80.38%
1-Day Range:
$1.62
$1.68
1-Week Range:
$1.58
$1.88
52-Week Range:
$0.87
$12.85
Outlook Therapeutics Inc Stock (OTLK) Company Profile
Name
Outlook Therapeutics Inc
Sector
Industry
Phone
(609) 619-3990
Address
111 S. WOOD AVENUE, ISELIN, NJ
Compare OTLK with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OTLK
Outlook Therapeutics Inc
|
1.635 | 52.51M | 0 | -51.50M | -47.10M | -4.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
485.24 | 123.34B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
698.66 | 76.09B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
649.20 | 39.34B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.32 | 32.49B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
119.97 | 28.26B | 3.30B | -501.07M | 1.03B | -2.1146 |
Outlook Therapeutics Inc Stock (OTLK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-02-24 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Mar-27-24 | Upgrade | BTIG Research | Neutral → Buy |
| Feb-15-24 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Jan-25-24 | Upgrade | Guggenheim | Neutral → Buy |
| Dec-27-23 | Upgrade | CapitalOne | Equal Weight → Overweight |
| Aug-31-23 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Aug-31-23 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Aug-30-23 | Downgrade | BTIG Research | Buy → Neutral |
| Aug-30-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Aug-30-23 | Downgrade | CapitalOne | Overweight → Equal Weight |
| Aug-30-23 | Downgrade | Guggenheim | Buy → Neutral |
| Jul-13-23 | Initiated | CapitalOne | Overweight |
| Apr-03-23 | Initiated | Guggenheim | Buy |
| Feb-06-23 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-31-22 | Initiated | BTIG Research | Buy |
| Sep-13-22 | Initiated | Chardan Capital Markets | Buy |
| Sep-11-19 | Initiated | Ladenburg Thalmann | Buy |
| May-16-19 | Initiated | Oppenheimer | Outperform |
| Apr-22-19 | Initiated | Ascendiant Capital Markets | Buy |
View All
Outlook Therapeutics Inc Stock (OTLK) Latest News
Research Analysts Set Expectations for OTLK Q2 Earnings - MarketBeat
Q1 Earnings Estimate for OTLK Issued By HC Wainwright - MarketBeat
What is HC Wainwright’s Estimate for OTLK Q1 Earnings? - Defense World
Outlook Therapeutics® Participates in the Virtual Investor 'Top 5 for '25” On-Demand Conference - The Manila Times
Outlook Therapeutics® Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference - GlobeNewswire
Can This First-Ever Approved Ophthalmic Bevacizumab Transform Eye Treatment in 2025? - StockTitan
Outlook Therapeutics' (OTLK) Neutral Rating Reaffirmed at Chardan Capital - MarketBeat
Outlook Therapeutics (NASDAQ:OTLK) Given New $3.00 Price Target at HC Wainwright - MarketBeat
Outlook Therapeutics (NASDAQ:OTLK) Price Target Cut to $3.00 by Analysts at HC Wainwright - Defense World
Outlook Therapeutics’ (OTLK) Neutral Rating Reaffirmed at Chardan Capital - Armenian Reporter
Outlook Therapeutics (NASDAQ:OTLK) Given “Neutral” Rating at Chardan Capital - Defense World
Outlook Therapeutics (NASDAQ:OTLK) Announces Earnings Results, Misses Estimates By $0.04 EPS - MarketBeat
Outlook Therapeutics stock target cut to $3 at H.C. Wainwright By Investing.com - Investing.com Nigeria
Coinbase To Rally Over 11%? Here Are 10 Top Analyst Forecasts For Tuesday - Benzinga
Outlook Therapeutics stock target cut to $3 at H.C. Wainwright - Investing.com India
Outlook Therapeutics (NASDAQ:OTLK) Releases Quarterly Earnings Results, Misses Expectations By $0.04 EPS - MarketBeat
ONS-5010 shows promise in wet AMD treatment, matching Lucentis - MSN
Outlook Therapeutics Reports Strong Earnings and Strategic Progress - MSN
Analyzing Scilex (NASDAQ:SCLX) and Outlook Therapeutics (NASDAQ:OTLK) - Defense World
Outlook Therapeutics, Inc. SEC 10-Q Report - TradingView
Outlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2025 and Provides Corporate Update - GlobeNewswire
Outlook Therapeutics Reports Financial Results For First Quarter Of 2025 -February 14, 2025 at 09:07 am EST - Marketscreener.com
Outlook Therapeutics Secures Funding and Board Restructures - MSN
Outlook Therapeutics Reports Financial Results for First Quarter Fiscal Year 2025 - TradingView
Outlook Therapeutics Advances ONS-5010 / LYTENAVA™ BLA Resubmission and Prepares for European Commercial Launch in 2025 - Nasdaq
Outlook Reports Stunning Earnings Turnaround: From $11.2M Loss to $17.4M Profit as European Launch Approaches - StockTitan
Analysts Set Outlook Therapeutics, Inc. (NASDAQ:OTLK) PT at $27.40 - MarketBeat
Outlook Therapeutics (OTLK) to Release Earnings on Wednesday - MarketBeat
Strategic Move: Biologics Deal-Making Veteran Takes CBO Role at Sonnet BioTherapeutics - StockTitan
Outlook Therapeutics (OTLK) Expected to Announce Quarterly Earnings on Wednesday - Defense World
Outlook Therapeutics, Inc. (NASDAQ:OTLK) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Outlook Therapeutics, Inc. (NASDAQ:OTLK) Receives $27.40 Consensus Target Price from Analysts - Defense World
Outlook Therapeutics (OTLK) Expected to Announce Earnings on Wednesday - MarketBeat
Outlook Therapeutics Inc (NASDAQ: OTLK) Has Succeeded In Attracting Investors This Year, The Stock Is Down -9.52% Year-To-Date – Marketing Sentinel - Marketing Sentinel
Holdings of Outlook Therapeutics Inc (OTLK) are aligned with the stars - SETE News
Outlook Therapeutics Inc (OTLK) produces promising results - US Post News
Outlook Therapeutics® Participates in Virtual Investor “What This Means” Segment - GlobeNewswire
Outlook Therapeutics Inc (OTLK) receives a Neutral rating from Chardan Capital Markets - Knox Daily
Analysis of Outlook Therapeutics (OTLK) - substack.com
Outlook Therapeutics® Participates in Virtual Investor "What This Means” Segment - The Manila Times
Outlook Therapeutics Inc Stock (OTLK) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.11%
0.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):